|Author: Jo Frowde. Scleroderma is highly variable. See Types of Scleroderma. Read Disclaimer|
Autoimmunity and Mycobacterium
|Scleroderma and Tuberculosis
Tuberculosis is not an autoimmune disease, however when it spreads outside the lungs, it can affect any part of the body and thus it can imitate many autoimmune diseases, especially other systemic diseases such as scleroderma and lupus. (Also see What is Scleroderma? and Systemic Lupus Erythematosus)
What is Tuberculosis? Tuberculosis is a bacterial disease usually affecting the lungs (pulmonary TB). Other parts of the body can also be affected, for example lymph nodes, kidneys, bones, joints, etc. (extrapulmonary TB). New York State Department of Health.
Tuberculosis is caused by mycobacterium tuberculosis. Over one third of the world's population has latent or active mycobacterial infection.
Pulmonary tuberculosis is contagious and is usually spread by coughs and sneezes after prolonged close contact. So, it is much more likely to catch it from a family member or co-worker who has not yet had sufficient antibiotics, than from exposure in stores or public transportation.
Mannose–binding lectin (MBL) deficiency and tuberculosis infection in patients with ankylosing spondylitis (AS). We found a significant association between MBL deficiency and higher risk of tuberculosis and urinary tract infection in patients with AS. PubMed, Clin Rheumatol, 09/06/2017. (Also see Ankylosing Spondylitis)
Tuberculosis is most well known for affecting the lungs. However in about 20% of cases it occurs outside of the lungs, and then it is called extrapulmonary, miliary, or disseminated tuberculosis.
Case Report: Extra pulmonary tuberculosis presenting as fever with massive splenomegaly and pancytopenia. We report the case of a 13-year old male who presented with fever, weight loss, pallor and massive splenomegaly with pancytopenia. PubMed, IDCases, 2016 Mar 2;4:20-2. (Also see Liver and Spleen Involvement)
The effect of anti-tuberculosis treatment on levels of anti-phospholipid and anti-neutrophil cytoplasmatic antibodies in patients with active tuberculosis. Anti-TB treatment may induce normalization of anti-lactoferrin and anti-myeloperoxidase (MPO), and de novo anti-proteinase 3 and MPO formation. PubMed, Rheumatol Int.
Mycobacterium tuberculosis triggers autoimmunity? It is important to screen all tuberculosis patients for autoantibody profile and should be followed up after the treatment for any flaring up of autoimmune related symptoms. PubMed, Indian J Tuberc.
Systemic Sclerosis (SSc) and the Risk of Tuberculosis (TB). In this nationwide study, the incidence of TB infection was significantly higher among patients with SSc than in controls without SSc and special care should be taken in managing patients with SSc who are at high risk for TB. PubMed, J Rheumatol.
The Transcriptional Signature of Active Tuberculosis Reflects Symptom Status in Extra–Pulmonary and Pulmonary Tuberculosis (TB). The transcriptional signature in extra–pulmonary TB demonstrated heterogeneity of gene expression reflective of symptom status, while the signature of pulmonary TB was distinct, based on a higher proportion of symptomatic individuals. PubMed, PLoS One, 2016 Oct 5;11(10):e0162220.
Extrapulmonary Tuberculosis Symptoms. Mycobacteria can infect virtually any part of the body and onset slowly, imitating many other diseases. General symptoms include fatigue, malaise, fever, weight loss, anorexia, fever. It can affect the kidneys, bladder, muscles, joints, bones, heart, central nervous system, lymph nodes, and gastrointestinal tract. Patient.info.
Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors (TNFi): a look beyond the baseline tuberculosis screening protocol. ‘Early TB’ was exceeded by TB occurring after 1 year of TNFi treatment, thereby, suggesting that further TB prevention measures were required. PubMed, Clin Rheumatol, 2018 Sep;37(9):2391-2397. (Also see Biologic Agents)
Interferon–gamma response to the treatment of active pulmonary and extra-pulmonary tuberculosis (PTB). After 6 months of effective anti–tuberculosis treatment, IFN-γ levels decreased significantly in PTB patients, largely over the initial 8 weeks of treatment. PubMed, Int J Tuberc Lung Dis, 2017 Oct 1;21(10):1145-1149.
WHO recommends new test, treatment plan for superbug strains of TB. The World Health Organization recommended a speedier, cheaper treatment plan for patients with superbug forms of tuberculosis (TB) — a change that should help cure thousands of the killer disease. Reuters Health, 05/12/2016.
Many thanks to our recent donors, Jack and Elizabeth Lewis, Chris Dokter, Margaret Roof, Network for Good, PayPal Charitable Giving Fund, United Way Snohomish and Arnold Slotkin. See ISN News for more donors. Click Here to Donate.
TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.
We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: